A detailed history of Kellner Capital, LLC transactions in Immuno Gen, Inc. stock. As of the latest transaction made, Kellner Capital, LLC holds 69,200 shares of IMGN stock, worth $0. This represents 3.7% of its overall portfolio holdings.

Number of Shares
69,200
Holding current value
$0
% of portfolio
3.7%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 07, 2024

BUY
$12.46 - $29.95 $862,232 - $2.07 Million
69,200 New
69,200 $2.05 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Kellner Capital, LLC Portfolio

Follow Kellner Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kellner Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kellner Capital, LLC with notifications on news.